|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
White blood cell count-based dose adjustments are regularly performed for known TPMT- deficient patients and results in a reduced risk of neutropenia and febrile neutropenia.
|
31635813 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the influence of <i>NUDT15 R139C</i> and thiopurine S-methyltransferase (<i>TPMT</i>) on azathioprine (AZA) induced leukopenia in patients with autoimmune hepatitis (AIH) and related cirrhosis.
|
31024313 |
2019 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TPMT and NUDT15 variants predict thiopurine-induced leukopenia.
|
31342537 |
2019 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apart from genetic variants in thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) genes, polymorphisms in FTO alpha-ketoglutarate dependent dioxygenase (FTO) were found predictive of thiopurine-induced leukopenia, albeit with conflicting results.
|
31813937 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the influence of <i>NUDT15 R139C</i>, thiopurine S-methyltransferase (<i>TPMT</i>), and 6-TGN on azathioprine (AZA) induced leukopenia in Chinese autoimmune patients.
|
29867468 |
2018 |
|
Leukopenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TPMT genotype and tertiles of TPMT activity were compared to relapse free survival and occurrence of adverse events, particularly leukopenia.
|
29630648 |
2018 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this report, we first provide detailed clinical and laboratory characteristics of AZA-induced leukopenia in a patient with SS with a mutant NUDT15 R139C genotype (TT allele) and normal TPMT activity.
|
29702976 |
2018 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sixty hundred and ninety-five patients (90.6%) included in the TOPIC-trial had no variant in TPMT, of which 45 (6.5%) developed leucopenia.
|
28914446 |
2017 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition to variation in TPMT (thiopurine S-methyltransferase), the NUDT15 p.R139C variant was recently identified to have a strong association with AZA-induced leukopenia.
|
28566182 |
2017 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to determine the relationship between thiopurine metabolite levels and therapeutic response, and to investigate the association of NUDT15, TPMT, and thiopurine metabolites with leukopenia in patients with CD.
|
29206869 |
2017 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There were strong associations of NUDT15 c.415C>T, c.36_37insGGAGTC, and c.52G>A with thiopurine-induced leukopenia (P = 1.81 × 10, P = 4.74 × 10 and P = 0.04, respectively), whereas there was no relevance for thiopurine S-methyltransferase genotypes (P = 0.25).
|
28570428 |
2017 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in TPMT might be associated with myelotoxicity and leukopenia in AZA treated patients, while ITPA variant alleles appear not to be linked with treatment-related side effects.
|
26674571 |
2016 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three non-synonymous SNPs, which we previously reported association with thiopurine-induced leukopenia, NUDT15 (p.Arg139Cys), SUCLA2 (p.Ser199Thr), and TPMT *3C were selected for epistasis analysis with the XDH variants.
|
26863601 |
2016 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
TPMT genotyping is not a sensitive tool for predicting thiopurine-induced leukopenia.
|
27665263 |
2016 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, TPMT genotype was not found to be correlated with the incidence of leukopenia (P = 0.44).
|
27604507 |
2016 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
TPMT*3C had a specificity of 100%, but a sensitivity of 8% for predicting leucopenia.A 6-TGN level between 225 and 420 pmol/8 × 10(8) RBC could be a therapeutic window in patients receiving AZA therapy, and it could likely predict leucopenia in the initial 12 weeks of AZA therapy and a reasonable chance of successful clinical response in CD patients.
|
27082580 |
2016 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
TPMT and NUDT15 gene sequencing was performed for patients who had experienced AZA-induced leukopenia.
|
26735160 |
2016 |
|
Leukopenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Variants in the gene encoding thiopurine S-methyltransferase (TPMT) alter its enzymatic activity, resulting in higher levels of thiopurine metabolites, which can cause leukopenia.
|
26072396 |
2015 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Heritable deficiency of TPMT enzyme activity and polymorphisms may lead to leukopenia.
|
24322830 |
2014 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In Koreans, this variant demonstrated sensitivity and specificity of 89.4% and 93.2%, respectively, for thiopurine-induced early leukopenia (in comparison to 12.1% and 97.6% for TPMT variants).
|
25108385 |
2014 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
In Koreans, this variant demonstrated sensitivity and specificity of 89.4% and 93.2%, respectively, for thiopurine-induced early leukopenia (in comparison to 12.1% and 97.6% for TPMT variants).
|
25108385 |
2014 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigated the effects of TPMT and hypoxanthine guanine phosphoribosyltransferase (HPRT) activities on 6-thioguanine nucleotides (6-TGNs) concentrations and thiopurine-induced leukopenia in patients with IBD.
|
21381155 |
2012 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Variant genotype thiopurine S-methyltransferase predisposes to development of leucopenia (P = 0.003, OR = 5, CI 95 %, 1.8058-13.8444).
|
22535280 |
2012 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variant genotype thiopurine S-methyltransferase predisposes to development of leucopenia (P = 0.003, OR = 5, CI 95 %, 1.8058-13.8444).
|
22535280 |
2012 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TPMT*3C had a specificity of 100% (163/163) but a sensitivity of 5.56% (2/36) for predicting leucopenia.
|
23149442 |
2012 |